Towards Healthcare
Epigenetics Market Size | Shares | Companies Report

Epigenetics Market Size (USD 61.15 Bn by 2033) Report

The report covers Epigenetics Market Trends and Companies Analysis including Roche Diagnostics, Thermo Fisher Scientific, Inc., Element Biosciences, Inc., Dovetail Genomics LLC., Illumina, Inc., GeneTex, Inc., PacBio, Merck KGaA, Eisai Co., Ltd., Novartis AG, Abcam Limited, Diagenode s.a., Active Motif, Inc., Epizyme, Inc., Domainex, Bio-Rad Laboratories, Inc., AsisChem Inc., BioVision Inc., and Epigenica. The report offers the value (in USD Billion) for the segments.

Epigenetics Market Size and Future Growth Analysis Report

The epigenetics market size was valued at US$ 14.70 billion in 2023 and is predicted to reach US$ 61.15 billion by the end of 2033, representing an impressive CAGR of 15.32% from 2024 to 2033. The decline in sequencing costs, the rise in next-generation sequencing applications worldwide, and product advancements are anticipated to propel the epigenetics market's expansion.

Epigenetics Market Size 2023 - 2033

Unlock Infinite Advantages: Subscribe to Annual Membership

Key Takeaways

  • North America held the largest market revenue share of 39% in 2023.
  • Asia Pacific is estimated to grow with the fastest CAGR of 17.73% during the forecast period.
  • By product, the reagents segment has contributed more than 34% of revenue share in 2023.
  • By product, the services segment is projected to grow at a CAGR of 17.70% during the forecast period.
  • By technology, the DNA methylation segment has held the largest revenue share of 46% in 2023.
  • By technology, the histone acetylation segment is expected to expand at the notable CAGR of 18.19% during the forecast period.
  • By application, the oncology segment dominated the market with the largest revenue share of 70% in 2023.
  • By application, the non-oncology segment is registering a remarkable CAGR of 16.32% during the forecast period.
  • By end-use, the academic research segment has recorded more than 39% of revenue share in 2023.
  • By end-use, the clinical research segment is expected to witness the fastest CAGR of 16.40% during the forecast period.

Industry at a Glance

The epigenetics market revolves around study, research, medicine, healthcare, pharmacy, and other disciplines associated with epigenetics. The study of epigenetics focuses on how cells regulate gene expression without altering the DNA sequence. Throughout the history of biology, one of the areas that has grown the fastest is epigenetics. In the animal and plant worlds, phenotypic variation among species is significantly influenced by epigenetics.

Despite this uncertainty, the field of epigenetics is vibrant, pushing the boundaries of technology while also questioning and updating long-held biological beliefs. The traditional genetic works are now viewed from new angles thanks to epigenetics, and when taken together, they aid in our understanding of the functions and interactions of DNA, RNA, proteins, and environment in heredity and the etiology of illness. In addition to helping to better understand the complexity of genetic control, cellular differentiation, embryology, aging, and illness, the epigenetics market is expected to make it possible to methodically investigate new therapeutic paths that may eventually lead to customized medicine.

Top Companies in the Epigenetics Market

  • Roche Diagnostics
  • Thermo Fisher Scientific, Inc.
  • Element Biosciences, Inc.
  • Dovetail Genomics LLC.
  • Illumina, Inc.
  • GeneTex, Inc.
  • PacBio
  • Merck KGaA
  • Eisai Co., Ltd.
  • Novartis AG
  • Abcam Limited
  • Diagenode s.a.
  • Active Motif, Inc.
  • Epizyme, Inc.
  • Domainex
  • Bio-Rad Laboratories, Inc.
  • AsisChem Inc.
  • BioVision Inc.
  • Epigenica

Recent Breakthrough by Epigenica in the Epigenetics Market

Company Name Epigenica
Headquarters Stockholm, Sweden
Breakthrough In June 2024, Epigenica, a start-up that is leading the way in the application of multiplex, high-throughput tools in epigenomic research, launched EpiFinder Genome, an extensive genome-wide profiling tool, and unveiled its EpiFinderTM Platform, which includes a patented high-throughput, multiplexing, quantitative ChIP-seq (hmqChIP-seq) technology. The company's main offering, EpiFinder Genome, targets up to eight markers simultaneously in up to 24 samples or independent repetitions. It is the first commercial kit of its sort. It produces quantifiable data that may be utilized to learn more about precision medicine, biomedical research, diagnostics, and medication development.

Recent Advancement by PacBio in the Epigenetics Market

Company Name PacBio
Headquarters California, U.S.
Breakthrough In May 2024, in an effort to help families dealing with uncommon disorders, Ambry Genetics and PacBio announced a partnership to sequence up to 7,000 human genomes. The researchers want to find novel, uncommon variants and comprehend the impact of epigenomics on illness manifestation by utilizing an extremely precise 5-base, long-read sequencing technique. The scientists intend to find novel Mendelian gene variations and more accurately classify previously found variants of uncertain importance by developing new processing methods for this genomic and epigenomic data.

Growing Research & Development Drive the Market

The epigenetics market is growing due to the continuous focus on research and development for developing therapies, drugs, and personalized medicines. Key players, along with government organizations, are making efforts to use epigenetics to understand the role of environmental factors in genetic modifications. Neurological problems and cancer are two examples of the many illnesses and diseases in which epigenetics is crucial. Researchers have discovered that variations in the epigenetic states of sick and healthy cells can act as useful disease indicators. Drug development has been greatly affected by epigenetics, with a number of medications and treatments that target epigenetic changes already on the market. Drug development and epigenetic research have a bright future ahead of them, with a particular emphasis on individualized care and customized therapies.

For instance,

  • In March 2024, Tally Health, a consumer longevity startup that seeks to transform how people age, announced the successful scientific validation of CheekAge, a cutting-edge next-generation aging clock durability. Technology: Tally Health has published in the scientific journal GeroScience and has promised to release its most recent findings for public assessment, all while maintaining openness. The business used DNA methylation samples, lifestyle and health data, and information from over 8,000 varied participants to build a patented epigenetic aging clock that uses buccal swabs to forecast age.

Genetic Discrimination is a Concern for the Epigenetics Market

A considerable amount of public concern has been raised over the past few decades by a few high-profile cases of genetic discrimination. There are disagreements about whether it is morally or legally acceptable to use a person's genetic information to deny some person access to a range of social benefits. When we talk about genetic discrimination, we generally mean unfair acts by insurance companies or employers that could be inclined to demand that people take a genetic test or reveal the findings. Nations all across the world have enacted a variety of public policies to solve this issue.

Personalized Medicines and Treatment Holds Great Opportunity for the Market’s Growth

A person's health and sickness can be better understood by studying their genome and the information that goes along with it. For accurate illness management and prediction, genomic techniques, including the detection of DNA sequence variants, transcriptomics, proteomics, and metabolomics, are helpful. These methods serve as helpful links between customized medicine and epigenetics. Patient-specific epigenetic and medication management data can be leveraged to personalize medical care. Scholars are now exploring the potential of employing epigenetic techniques to create tailored treatment strategies for certain ailments, including schizophrenia, psychological disorders, and heart problems. There is a lot of room for expansion in the epigenetics market due to the increasing demand for medications and individualized care.

For instance,

  • In April 2024, with an official spring launch this year, Generation Lab will present what it calls the first clinically validated test that measures biological age and illness risk using epigenetic information. The device is presently undergoing internal testing by the corporation, with an official launch scheduled for the second quarter of 2024. By assessing individuals both before and after they receive individualized therapies and suggestions based on data from their genomes, Generation Lab seeks to give a focused approach to reversing the aging process.

Report Highlights

Product Insights

By product type, the reagents segment dominated the epigenetics market in 2023. Using a variety of reagents is essential in laboratory settings to carry out experiments, carry out chemical reactions, and get correct findings. Reagents are essential for the binding of antibodies, the facilitation of analytical procedures, and the synthesis of targeted molecules. There are several grades of reagents available, each having specialized uses and properties based on the application. It is essential for scientists and researchers to comprehend the many kinds of laboratory reagents and how to utilize them in order to carry out studies efficiently and provide reliable findings. Activities such as DNA methylation, RNA transcription, histone medication, DNA purification, PCR, assay, etc., are conducted in epigenetics for which reagents are needed.

Technology Insights

By technology, the DNA methylation segment dominated the epigenetics market with the largest share. Histone modification and non-coding RNA-mediated control of gene expression are two additional common epigenetic processes that impact gene expression. DNA methylation is one of these mechanisms, suppressing gene expression in different ways and influencing the activity of these other two mechanisms. Of the three known methods of epigenetic control of gene expression, DNA methylation is the one that has been researched the most. Up to now, a substantial body of research has been conducted to demonstrate the pivotal role this mechanism plays in the emergence of several autoimmune and neurodegenerative disorders in people.

For instance,

  • In February 2024, Wasatch Biolabs (WBL), an Oxford Nanopore Technologies facility certified by Renew Biotechnologies, offers researchers and clinical service providers a discreet Targeted DNA Methylation Sequencing Service. With an enrichment of 400–2300x, WBL may use this technology to construct customized methylation panels that target an unparalleled number of hundreds to thousands of genomic sites of interest. This is because it does not rely on the two most prominent drawbacks of targeted methylation analysis, which are bisulfite conversion and amplification.

By technology, the histone acetylation segment is expected to grow at the fastest rate during the forecast period. Primarily, histone acetylation is an epigenetic modification that affects gene expression by determining whether transcription factors can access or not access certain genes. In order to activate the transcription of genes, histone acetylation is necessary. Since it was the first alteration of histones to be shown to affect transcriptional control, acetylation is one of the most researched histone modifications. Epigenetics can be used to study the regulation of many other cellular processes, such as cellular differentiation, nuclear import, neuronal repression, DNA replication and repair, and cell cycle regulation, along with the involvement of histone acetylation in cell proliferation, apoptosis, and regulation of many other functions.

Applications Insights

By application, the oncology segment dominated the epigenetics market in 2023. Since the response of cancer cells to therapeutic treatments is governed by their epigenome, progress in understanding the landscape of cancer epigenetics is imperative as precision medicine becomes more practically applied. Novel insights into several cancer treatment models that identify aberrant epigenetic modifications are offered by advanced epigenetic therapy. In the field of malignant tumor therapy and individualized precision diagnostics, this is a significant advancement. The market for epigenetics is becoming increasingly important for oncology since cancer is becoming more common, particularly as a result of changing environmental factors.

For instance,

  • According to the World Health Organization, it is anticipated that there will be over 35 million new cases of cancer in 2050, a 77% increase over the projected 20 million cases in 2022. 20 million new instances of cancer and 9.7 million deaths from the disease are predicted for 2022. 53.5 million people were predicted to still be alive five years after receiving a cancer diagnosis. Cancer affects 1 in 5 persons at some point in their lives. Lung cancer accounted for 2.5 million new cases globally, or 12.4% of all new cases, making it the most frequent cancer. Next in order of incidence was colon cancer (1.9 million cases, 9.6%), prostate cancer (1.5 million cases, 7.3%), stomach cancer (970,000 cases, 4.9%), and female breast cancer (2.3 million cases, 11.6%).

By application, the non-oncology segment is estimated to grow at the fastest CAGR during the forecast period. The focus of research over the past 20 years has been on developing epigenetic therapies to address oncological pathways and identifying epigenetic therapeutic targets in cancer. However, as evidence of the relevance of epigenetic pathways to numerous non-oncological diseases grows, scientists are becoming more interested in this area. Epigenetics can help lower the burden of diabetes and cardiovascular illnesses, two non-oncology diseases that are on the rise.

For instance,

  • Cardiovascular disease is the world's top cause of mortality for both men and women (CVD). By 2023, there will be eight billion people on the planet! Of these, at least 620 million people globally have heart and circulation diseases. Over 60 million people worldwide are affected by heart and circulation disorders each year. It is estimated that one in thirteen people globally suffer from a cardiac or circulation issue.
  • An estimated 422 million people worldwide—most of whom reside in low- and middle-income nations—have diabetes. The disease is directly responsible for 1.5 million fatalities annually, and within the next 30 years, it is expected to affect 1.3 billion people.

End-use Insights

By end-use, the clinical research segment is expected to witness the fastest growth during the forecast period. The epigenetics market is at a budding stage and is growing at a high pace. Key players and government organizations are making efforts to incorporate epigenetics in the development of drugs or medicines for the treatment of various diseases. Clinical research is continuously occurring to study how factors beyond the genetic code impact functioning and how they can be used to understand further the functions that occur in the body, which may or may not lead to serious conditions.

Regional Insights

By region, North America held the largest epigenetics market share in 2023. North America significantly contributes to the market's growth due to its technological advancements, government support, and the presence of key market players. The U.S. and Canada significantly contribute to the growth. Significant public funding, as well as private contributions, support the U.S. epigenetics market. The need for sophisticated diagnostic technologies and tailored therapy is driven by the increasing frequency of chronic illnesses, particularly cancer, in the nation.

For instance,

  • According to the U.S. Department of Health and Human Services, 129 million Americans are thought to have at least one significant chronic illness, such as diabetes, cancer, heart disease, obesity, or hypertension. A growing number of Americans are coping with two or more chronic diseases, and 12% are managing five or more. Chronic illness affects people personally as well as has a significant influence on the US healthcare system. The management and treatment of chronic illnesses and mental health disorders account for around 90% of the $4.1 trillion in healthcare spending that occurs annually.

Although the Canadian epigenetics industry is still smaller than the American one, it is expanding quickly as a result of increased government funding and research efforts. Significant funding for genetic and epigenetic research is provided by the Canadian Institutes of Health Research (CIHR) and other organizations. Significant breakthroughs in the subject have been made possible by the active participation of Canadian scholars in international partnerships.

By region, Asia Pacific is estimated to grow with the fastest CAGR during the forecast period. The region is growing continuously with emerging technology and contributions by various countries, including China, India, Japan, and South Korea. Among these countries, China and India play significant roles in the growth of the epigenetics market in the Asia-Pacific region.

Asian nations continue to embrace Chinese Medicine (CM), which has been a part of human health care for several millennia. In the wake of constantly advancing molecular technology, CM research on epigenetics has clearly improved lately. Epigenetics' holistic, dynamic, individual, and environment-interacting qualities align well with the fundamental principles of Traditional Chinese Medicine (TCM), which is practiced extensively in China and many other Asian and Western nations. The process of DNA methylation modification is regulated by TCM, which has been shown to have a significant anti-tumor impact in several investigations on the anti-tumor effect of TCM.

Perception of Epigenetic Screening

Perception % Responding
One of today's most exciting biological target areas, somewhat comparable to kinase situation, just time is needed to develop 51%
It will remain challenging until the biology and screening tools catch up with the hype 41%
The lack of follow-up biology will create a significant obstacle for the foreseeable future 4%
It will never be like the kinase situation as the assays and methodologies are too diverse 4%
No point in screening or profiling targets that have unknown disease relevance 0%

Most people (51%) think epigenetic screening is a very promising area of research, similar to kinase research, but needs more time to develop. A smaller group (41%) is more cautious, thinking it's overhyped and needs better understanding of the biology and tools. Only a few (8%) have a negative view of epigenetic screening.

Recent Developments in Epigenetics Market

  • In January 2024, Moonwalk Biosciences, a genomic medicine startup that is leading the way in precision epigenetic therapies, reported that $57 million in seed and Series A funding from GV, Khosla Ventures, Alpha Wave Ventures, ARCH Venture Partners, Future Ventures, and YK Bioventures had been completed. The funding will help Moonwalk build its pipeline of epigenetic medicines closer to the clinic and support the development of its epigenetic profiling and engineering technology platform.
  • In November 2023, FOXO Technologies, a business that specializes in epigenetic biomarker technology, disclosed its intentions to launch a direct-to-consumer product line that utilizes artificial intelligence and epigenetic data. According to the business, the subscription-based service will use FOXO's machine-learning algorithms to analyze epigenetic biomarkers connected with health outcomes and validated clinical data in order to deliver individualized health and wellness recommendations.
  • In June 2023, two new skincare products with scientific backing have been introduced by the upscale, high-tech company LYMA to address the causes of aging. The company's most recent invention, a new Serum and Cream Starter Kit, marks its entry into the skincare market. The products target the eight processes of skin aging and aim to "stimulate unprecedented transformation to the appearance and future of your skin," drawing on the science of epigenetics.

Segments Covered in Epigenetics Market Report

By Product

  • Reagents
  • Kits
    • Chip Sequencing Kit
    • Whole Genomic Amplification Kit
    • Bisulfite Conversion Kit
    • RNA sequencing Kit
    • Others
  • Instruments
  • Enzymes
  • Services

By Technology

  • DNA Methylation
  • Histone Methylation
  • Histone Acetylation
  • Large non-coding RNA
  • MicroRNA Modification
  • Chromatin Structures

By Application

  • Oncology
    • Solid Tumors
    • Liquid Tumors
  • Non-oncology Oncology
    • Inflammatory Diseases
    • Metabolic Diseases
    • Infectious Diseases
    • Cardiovascular Diseases
    • Others

By End-use

  • Academic Research
  • Clinical Research
  • Hospitals & Clinics
  • Pharmaceutical & Biotechnology Companies
  • Other Users

By Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Thailand
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • MEA
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Proceed To Buy

USD 5400
USD 3800
USD 2100
USD 2100
USD 7500

About The Author

Deepa has certified the degree of Master’s in Pharmacy in the Pharmaceutical Quality Assurance department from Dr D.Y. Patil College of Pharmacy. Her research is focused on the healthcare industry. She is the author or co-author of four Review Articles, which include Solid dispersion a strategic method for poorly soluble drugs and solubility improvement techniques for poorly soluble drugs, Herbal Drugs Used In Treatment Of Cataracts, Nano sponges And Their Application in Cancer Prevention and Ayurvedic Remedies of Peptic ulcer. She has also published a Research Article on the Formulation and Evaluation of Mucoadhesive Tablets of Miconazole cocrystal which was published in GIS Science Journal Volume 9 Issue 8. Her passion for secondary research and desire to take on the challenge of solving unresolved issues is making her flourish is the in the research sector.


Physical activity, healthy eating, changes in lifestyle, and changes in the environment can impact epigenetics positively.

Neurological disorders, cancer, autoimmune disorders, Alzheimers, Parkinsons disease, Huntingtons, schizophrenia, and circulatory diseases.

DNA methylation, non-coding RNA action, and histone modification.

National Institute of Health, National Library of Medicine, NHS England, American Cancer Society, World Health Organization, and U.S. Department of Health and Human Services.